Lantheus Holdings, Inc.

We are a radiopharmaceutical-focused company that helps clinicians find, fight, and follow diseases to improve patient outcomes. Our products are categorized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology products assist healthcare professionals (HCPs) in finding, fighting, and following cancer. Our Precision Diagnostic products help HCPs find and follow diseases. Strategic Partnerships include biomarkers and digital solutions supporting partners' therapeutic development, out-licensing non-core assets, geographical asset optimization, and contract development and manufacturing organization (CDMO) revenue from Evergreen. Our commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists in various clinical settings. We believe our diagnostic products provide information for HCPs to better detect and characterize, or rule out, disease, potentially leading to better patient outcomes, reduced patient risk, and limited overall costs. We produce and market our products across the United States, primarily selling to hospitals, independent imaging centers, and government facilities. Outside the United States, we sell through direct distribution and third-party relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America, and by licensing exclusive development and commercialization rights for certain products. We are headquartered in Massachusetts, with offices in New Jersey, Canada, Germany, Switzerland, Sweden, and the United Kingdom.